莱美药业
(300006)
| 流通市值：58.70亿 | | | 总市值：58.71亿 |
| 流通股本：10.56亿 | | | 总股本：10.56亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 350,442,837.47 | 182,210,103.8 | 775,686,202.33 | 581,062,830.69 |
| 营业收入 | 350,442,837.47 | 182,210,103.8 | 775,686,202.33 | 581,062,830.69 |
| 二、营业总成本 | 360,253,634.53 | 189,415,653.02 | 853,327,387.5 | 627,339,724.72 |
| 营业成本 | 168,550,844.69 | 81,977,007.61 | 343,105,071.68 | 259,556,669.63 |
| 税金及附加 | 6,400,856.19 | 3,419,864.27 | 13,780,963.76 | 10,110,552.52 |
| 销售费用 | 116,389,693.01 | 66,664,631.74 | 309,326,447.25 | 227,160,897.57 |
| 管理费用 | 55,110,987.91 | 28,865,032.81 | 134,567,101.86 | 99,528,548.21 |
| 研发费用 | 17,916,066.7 | 9,550,934.42 | 62,497,329.05 | 39,186,240.35 |
| 财务费用 | -4,114,813.97 | -1,061,817.83 | -9,949,526.1 | -8,203,183.56 |
| 其中:利息费用 | 5,107,964.98 | 3,958,472.16 | 13,764,626.65 | 10,384,817.24 |
| 其中:利息收入 | 10,603,438.99 | 5,714,188.79 | 24,795,959.14 | 19,195,282.77 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -18,566,597.1 | -12,695,314.25 | -21,143,556.14 | -16,769,818.88 |
| 资产处置收益 | 17,687.78 | 16,695.41 | 34,375.22 | 9,958.47 |
| 资产减值损失(新) | -478,170.55 | -422,739.6 | -70,683,052.13 | -3,555,634.45 |
| 信用减值损失(新) | -3,423,227.22 | -98,694.93 | -4,870,106.12 | -4,293,890.95 |
| 其他收益 | 10,069,899.62 | 3,355,412.13 | 28,134,436.06 | 23,496,778.96 |
| 四、营业利润 | -22,191,204.53 | -17,050,190.46 | -146,169,088.28 | -47,389,500.88 |
| 加:营业外收入 | 38,334 | 1,727.29 | 153,262.31 | 90,213.49 |
| 减:营业外支出 | 252,780.84 | 59,376.84 | 796,627.4 | 288,251.25 |
| 五、利润总额 | -22,405,651.37 | -17,107,840.01 | -146,812,453.37 | -47,587,538.64 |
| 减:所得税费用 | 249,497.41 | -3,526,035.82 | -20,280,536.57 | -2,665,695.98 |
| 六、净利润 | -22,655,148.78 | -13,581,804.19 | -126,531,916.8 | -44,921,842.66 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -22,655,148.78 | -13,581,804.19 | -126,531,916.8 | -44,921,842.66 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -23,417,471.67 | -15,012,683.6 | -134,705,331.86 | -45,917,207.27 |
| 少数股东损益 | 762,322.89 | 1,430,879.41 | 8,173,415.06 | 995,364.61 |
| 扣除非经常损益后的净利润 | -25,774,908.44 | -15,470,280.23 | -139,455,695.08 | -48,379,031 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | -0.01 | -0.13 | -0.04 |
| (二)稀释每股收益 | -0.02 | -0.01 | -0.13 | -0.04 |
| 八、其他综合收益 | -7,299,970.49 | - | -16,260,693.68 | - |
| 归属于母公司股东的其他综合收益 | -7,299,970.49 | - | -16,260,693.68 | - |
| 九、综合收益总额 | -29,955,119.27 | -13,581,804.19 | -142,792,610.48 | -44,921,842.66 |
| 归属于母公司股东的综合收益总额 | -30,717,442.16 | -15,012,683.6 | -150,966,025.54 | -45,917,207.27 |
| 归属于少数股东的综合收益总额 | 762,322.89 | 1,430,879.41 | 8,173,415.06 | 995,364.61 |
| 公告日期 | 2026-08-21 | 2026-04-23 | 2026-03-19 | 2025-10-22 |
| 审计意见(境内) | | | 标准无保留意见 | |